{"id":55831,"date":"2023-04-14T13:05:47","date_gmt":"2023-04-14T11:05:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/"},"modified":"2023-04-14T13:05:47","modified_gmt":"2023-04-14T11:05:47","slug":"phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/","title":{"rendered":"Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples"},"content":{"rendered":"
\n

\nThe Element AVITI\u2122 System rapidly delivers high-quality, cost-effective data to accelerate cytogenomic research on Phase Genomics\u2019 OncoTerra\u2122 Platform<\/i><\/p>\n

SEATTLE & SAN DIEGO–(BUSINESS WIRE)–#cytogenetics<\/a>—Phase Genomics, Inc<\/a>., a leading developer of cutting-edge genomic solutions, and Element Biosciences<\/a>, the developer of an innovative DNA sequencing platform disrupting genomics, today released new details of their first collaboration leveraging Phase Genomics\u2019 proprietary OncoTerra\u2122 cytogenomics platform and the Element AVITI System for next generation sequencing (NGS). Data generated from AVITI showed improvements in several key sequencing metrics, making it an ideal technology to pair with the proximity ligation-based OncoTerra\u2122 cytogenomics platform for cancer research.<\/p>\n

<\/a><\/p>\n

\n\u201cWe\u2019re extending the application of our core technologies into the oncology space, ensuring Phase Genomics\u2019 next-generation cytogenomic tools deliver unparalleled precision, speed, and efficiency. We\u2019re excited by what we\u2019re seeing as a result of this recent work with Element,\u201d said Ivan Liachko, PhD, co-founder and CEO of Phase Genomics. \u201cAlthough OncoTerra is NGS platform agnostic, the high quality and accuracy of Element\u2019s AVITI System make it a great option for data generation in next generation cytogenomics.\u201d<\/p>\n

\nThe OncoTerra Platform paired with the AVITI System enables high-resolution cytogenomic analysis of solid-tumor samples, including archival formats, such as formalin-fixed, paraffin-embedded (FFPE) samples, that are largely unsuitable for conventional cytogenetic assays. Data generated on the Element AVITI System shows a lower level of duplicates and a higher proportion of high-quality read pairs. This increases the efficiency of OncoTerra library sequencing. OncoTerra delivers genome-wide cytogenomic insights from a wide array of sample types, including blood, fresh, and frozen tissues. Phase Genomics\u2019 OncoTerra platform is the first offering to deliver the value of scalable cytogenomics for solid-tumor malignancies in the research setting.<\/p>\n

\n\u201cOur work with Phase Genomics marks Element Biosciences\u2019 first foray into the next-generation cytogenomics space for oncology,\u201d said Shawn Levy, PhD, CSO and SVP of Applications at Element Biosciences. \u201cOur collaborative work with Phase Genomics underscores the versatility of the AVITI System in accurate genomic characterization of clinically relevant samples. Phase Genomics\u2019 innovative approach to cytogenomics amplifies our joint impact in oncology research today, advancing the latest technology toward the clinic.\u201d<\/p>\n

\nThe OncoTerra platform leverages data from ubiquitous short-read sequencing technologies, like the Element AVITI NGS system, to identify novel and known genomic alterations. This information is key for oncology research applications. Phase Genomics and Element will share additional details and an application note at the upcoming AACR conference, April 14-19 (Phase Genomics booth #561, Element Biosciences booth #559). The application note demonstrates that with a single NGS-based assay, OncoTerra surpasses the breadth and depth of insights from current front-line cytogenetic diagnostics, including karyotyping, fluorescence in situ<\/i> hybridization (FISH), and chromosomal microarrays.<\/p>\n

\nFollow Phase Genomics on Twitter<\/a> and LinkedIn<\/a> for the latest news and information and visit the Phase Genomics team at AACR, April 14-19, at booth #561.<\/p>\n

\nAbout Phase Genomics<\/b><\/p>\n

\nPhase Genomics applies proprietary proximity ligation technology to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. In addition to a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples, they also offer an industry-leading genome and metagenome assembly and analysis software.<\/p>\n

\nBased in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company\u2019s mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.<\/p>\n

\nAbout Element Biosciences, Inc.<\/b><\/p>\n

\nElement Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. To learn more about Element, please visit www.elementbiosciences.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nEric Schudiske
\n
Phase Genomics
\n
eric@s2spr.com<\/a><\/p>\n

\nKristi Heim
\n
Element Biosciences
\n
Kristi.Heim@elembio.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The Element AVITI\u2122 System rapidly delivers high-quality, cost-effective data to accelerate cytogenomic research on Phase Genomics\u2019 OncoTerra\u2122 Platform SEATTLE & SAN DIEGO–(BUSINESS WIRE)–#cytogenetics—Phase Genomics, Inc., a leading developer of cutting-edge genomic solutions, and Element Biosciences, the developer of an innovative DNA sequencing platform disrupting genomics, today released new details of their first collaboration leveraging Phase … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55831","6":"format-standard","7":"category-industry"},"yoast_head":"\nPhase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The Element AVITI\u2122 System rapidly delivers high-quality, cost-effective data to accelerate cytogenomic research on Phase Genomics\u2019 OncoTerra\u2122 Platform SEATTLE & SAN DIEGO–(BUSINESS WIRE)–#cytogenetics—Phase Genomics, Inc., a leading developer of cutting-edge genomic solutions, and Element Biosciences, the developer of an innovative DNA sequencing platform disrupting genomics, today released new details of their first collaboration leveraging Phase ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-14T11:05:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230414005082\/en\/1763852\/21\/PGlogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples\",\"datePublished\":\"2023-04-14T11:05:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/\"},\"wordCount\":666,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230414005082\\\/en\\\/1763852\\\/21\\\/PGlogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/\",\"name\":\"Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230414005082\\\/en\\\/1763852\\\/21\\\/PGlogo.jpg\",\"datePublished\":\"2023-04-14T11:05:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230414005082\\\/en\\\/1763852\\\/21\\\/PGlogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230414005082\\\/en\\\/1763852\\\/21\\\/PGlogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/","og_locale":"en_US","og_type":"article","og_title":"Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples - Pharma Trend","og_description":"The Element AVITI\u2122 System rapidly delivers high-quality, cost-effective data to accelerate cytogenomic research on Phase Genomics\u2019 OncoTerra\u2122 Platform SEATTLE & SAN DIEGO–(BUSINESS WIRE)–#cytogenetics—Phase Genomics, Inc., a leading developer of cutting-edge genomic solutions, and Element Biosciences, the developer of an innovative DNA sequencing platform disrupting genomics, today released new details of their first collaboration leveraging Phase ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-14T11:05:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230414005082\/en\/1763852\/21\/PGlogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples","datePublished":"2023-04-14T11:05:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/"},"wordCount":666,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230414005082\/en\/1763852\/21\/PGlogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/","url":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/","name":"Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230414005082\/en\/1763852\/21\/PGlogo.jpg","datePublished":"2023-04-14T11:05:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230414005082\/en\/1763852\/21\/PGlogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230414005082\/en\/1763852\/21\/PGlogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/phase-genomics-collaborates-with-element-biosciences-to-optimize-cytogenomics-for-liquid-and-solid-tumor-samples\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55831"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55831\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}